Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of JTZ-951 in ESRD Patients on Hemodialysis
NCT02805244Phase 1Completed
- Sponsor
- Akros Pharma Inc.
- Start
- Jun 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enarodustat in anemia of chronic kidney disease (CKD-A), sponsored by Akros Pharma Inc. Primary endpoints: Radioactivity concentration in urine, feces and dialysate, Radioactivity concentration in whole blood and plasma and 6 more. Started Jun 2016; status: completed.
02
Drugs
enarodustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT02805244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02805244.